It was also shown that a combination of buparlisib with the anti-EGFR monoclonal antibody cetuximab exerts a synergistic effect on tumor inhibition in wild-type or PIK3CA mutant HNSCC cell lines [67] as well as in a xenograft model of HNSCC [68]. This evidence concerns the gene PIK3CA and neoplasm.